ArticleKidney3602026
Early Lymphoid Aggregates in Protocol Kidney Allograft Biopsies: Molecular Characterization and Association with Long-Term Kidney Allograft Outcome.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
key pointsStable kidney transplant recipients with early stage 1 lymphoid aggregates displayed gene signatures indicative of a tolerogenic immune environment. Participants with early stage 1 lymphoid aggregates demonstrated a trend toward better kidney function trajectories and lower risk of graft failure. Early stage 1 lymphoid aggregates may represent beneficial immune surveillance mechanisms promoting long-term graft stability in low-risk transplant recipients.
backgroundThe presence of lymphoid tissues and their effect on long-term kidney graft outcome remains unclear. This study investigates the occurrence, molecular and phenotypic characteristics of lymphoid aggregates (LA) in protocol biopsies of clinically stable kidney transplant recipients, and their correlation with long-term clinical outcome.
methodsWe retrospectively analyzed 414 protocol biopsies from a multicenter cohort of 278 stable kidney transplant recipients taken at 6, 12, or 24 months post-transplant. On a subset of 16 biopsies at 6 months post-transplant, mRNA gene expression analysis was performed using Nanostring Banff Human Organ Transplant panel alongside phenotypic analysis with immunostaining for developmental staging of LA. Finally, the presence of LA was correlated to various clinical kidney allograft outcomes.
resultsStage 1 LA were characterized by upregulation of genes linked to immune regulation ( LAG3, CTLA4, FOXP3 ), T -cell signaling, and chemotaxis pathways, with enrichment of regulatory T cells, memory T cells, T follicular helper cells, and dendritic cells. Immunohistochemistry confirmed higher numbers of FOXP3+ regulatory T cells and dendritic cells in stage 1 LA, while high endothelial venules were absent. Over follow-up, participants with stage 1 LA showed slightly higher eGFR values and a trend toward better graft survival compared with those without LA or with stage 2 LA, although most differences did not reach statistical significance.
conclusionsIn stable kidney transplant recipients, stage 1 LA displayed molecular and phenotypic features consistent with a regulated immune environment. The molecular and immunohistochemical analysis of stage 1 LA suggests a more regulatory molecular phenotype and composition, which may contribute to better long-term graft survival observed in this cohort of functionally stable transplant recipients. Observed trends toward more favorable outcomes suggest that early LA may not be deleterious and could represent local immune regulation, although larger prospective studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.